

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.


Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel

Appendix


Appendix Table. Sensitivity analyses for vaccine effectiveness (VE) against SARS-CoV-2 infection in 5-11 year old children by age group and period, 20 January to 15 February 2022, Israel.

Sensitivity analysis group	Time since 2 nd vaccine dose (Days)	Cases		Controls		Total cases (N)	Total controls (N)	VE (95% CI)
		2 nd dose recipients (N)	Unvaccinated (N)	2 nd dose recipients (N)	Unvaccinated (N)			
5-8 yo*	8-14	853	33,102	1,994	31,961	33,955	33,955	60.0 (56.5 to 63.2)
	15-21	904	33,102	1,936	32,070	34,006	34,006	56.6 (52.8 to 60.1)
	22-28	824	32,967	1,564	32,227	33,791	33,791	49.6 (45.0 to 53.9)
	29-35	1,265	33,041	2,240	32,066	34,306	34,306	46.9 (42.9 to 50.6)
	36-42	1,087	32,899	1,704	32,282	33,986	33,986	39.4 (34.3 to 44.0)
9-11 yo	8-14	767	21,721	1,683	20,805	22,488	22,488	58.4 (54.4 to 62.0)
	15-21	920	21,643	1,717	20,846	22,563	22,563	50.6 (46.2 to 54.7)
	22-28	929	21,510	1,514	20,925	22,439	22,439	42.4 (37.2 to 47.2)
	29-35	1,466	21,750	2,370	20,846	23,216	23,216	44.8 (40.7 to 48.7)
	36-42	1,348	21,681	2,063	20,966	23,029	23,029	39.6 (34.8 to 43.9)
Period 1	8-14	1,362	43,852	3,059	42,155	45,214	45,214	59.0 (56.1 to 61.7)
	15-21	1,339	43,681	2,715	42,305	45,020	45,020	54.1 (50.8 to 57.1)
	22-28	1,160	43,486	2,150	42,496	44,646	44,646	48.8 (44.8 to 52.5)
	29-35	2,159	43,713	3,604	42,268	45,872	45,872	45.2 (41.9 to 48.3)
	36-42	1,904	43,608	2,915	42,597	45,512	45,512	39.0 (35.1 to 42.7)
Period 2	8-14	294	10,927	586	10,635	11,221	11,221	52.6 (45.1 to 59.1)
	15-21	491	11,056	923	10,624	11,547	11,547	50.5 (44.4 to 56.0)
	22-28	575	11,008	949	10,634	11,583	11,583	43.5 (36.8 to 49.4)
	29-35	586	11,036	993	10,629	11,622	11,622	44.8 (38.5 to 50.5)
	36-42	533	10,961	858	10,636	11,494	11,494	41.1 (34.0 to 47.5)

*yo –years old



Appendix Figure 1. A flow diagram of PCR tests eligible for selecting cases and controls for matched case-control analysis.



Appendix Figure 2. Time from first SARS-CoV-2 PCR sampling to hospitalization (N=102).